Free Trial
NYSE:HQL

abrdn Life Sciences Investors (HQL) Stock Price, News & Analysis

abrdn Life Sciences Investors logo
$17.70 -0.47 (-2.61%)
Closing price 10/2/2026 03:59 PM Eastern
Extended Trading
$17.69 -0.01 (-0.03%)
As of 10/2/2026 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About abrdn Life Sciences Investors Stock (NYSE:HQL)

Advanced

Key Stats

Today's Range
$17.60
▼
$18.29
50-Day Range
$17.70
▼
$22.64
52-Week Range
$15.60
▼
$22.67
Volume
245,630 shs
Average Volume
115,730 shs
Market Capitalization
$538.14 million
P/E Ratio
N/A
Dividend Yield
12.66%
Price Target
N/A
Consensus Rating
N/A

Company Overview

abrdn Life Sciences Investors (NYSE: HQL) is a diversified, closed-end investment company focused on the life sciences sector. The fund seeks long-term capital appreciation by investing in companies involved in biotechnology, pharmaceuticals, medical devices, diagnostics, healthcare services and related industries.

Its portfolio may include both publicly traded and privately held businesses across various stages of development, from emerging companies developing new therapies and technologies to more established healthcare enterprises. Through these investments, the fund provides exposure to areas such as drug discovery, medical research, therapeutic products and healthcare innovation.

The fund was formerly known as Tekla Life Sciences Investors and is managed by abrdn, a global investment company. Its investments may span life sciences businesses in the United States and international markets, subject to the fund’s investment strategy and policies.

AI Generated. May Contain Errors.

Receive HQL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for abrdn Life Sciences Investors and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HQL Stock News Headlines

HQL: The Rally That Makes Growth Harder (Rating Downgrade)
abrdn Life Sciences Investors Q2 2026 Commentary
First Look: Elon’s “Starphone”
Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that.tc pixel
abrdn Life Sciences Investors Q1 2026 Commentary
HQL: Attractive Outlook With Growth Of GLP-1 Market
Abrdn Life Sciences Investors Fund Q4 2025 Commentary
See More Headlines

HQL Stock Analysis - Frequently Asked Questions

abrdn Life Sciences Investors' stock was trading at $16.79 at the beginning of the year. Since then, HQL stock has increased by 5.4% and is now trading at $17.6960.

Shares of HQL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that abrdn Life Sciences Investors investors own include Rithm Capital (RITM), DoubleLine Income Solutions Fund (DSL), Verizon Communications (VZ), International Business Machines (IBM), Eaton Vance Tax-Managed Global Diversified Equity Income Fund (EXG) and Energy Transfer (ET).

Company Calendar

Record date for 9/30 Dividend
8/24/2026
Ex-Dividend for 9/30 Dividend
8/24/2026
Record date for 8/31 Dividend
8/24/2026
Ex-Dividend for 8/31 Dividend
8/24/2026
Dividend Payable
8/31/2026
Dividend Payable
9/30/2026
Today
10/04/2026
Fiscal Year End
9/30/2027

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Finance
Industry
Capital Markets
Sub-Industry
N/A
Current Symbol
NYSE:HQL
CIK
884121
Employees
N/A
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
30,410,000
Free Float
27,349,000
Market Cap
$538.14 million
Optionable
Not Optionable
Beta
0.77
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NYSE:HQL) was last updated on 10/4/2026 by MarketBeat.com Staff.
From Our Partners